ENZON PHARMACEUTICALS, INC. (OTCMKTS:ENZN) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
The 2018 annual meeting of stockholders of Enzon Pharmaceuticals, Inc. (the “Company”) was held on August 9, 2018. At the 2018 annual meeting of stockholders, the Company’s stockholders voted on the following matters as described in the Company’s proxy materials: (1) the election of three directors, each for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, (2) the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 and (3) the approval, on an advisory basis, of the compensation of the Company’s named executive officers. A total of 36,439,678 shares of common stock were present or represented by proxy at the 2018 annual meeting of stockholders, representing approximately 82.4% of the total shares of common stock entitled to vote at the 2018 annual meeting of stockholders.
| 1. | Election of Directors – The Company’s stockholders elected each of the following individuals as a director for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, as set forth below: |
|
Nominee |
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| Jonathan Christodoro | 12,393,843 | 310,706 | 32,047 | 23,703,082 |
| Odysseas Kostas, M.D. | 12,363,767 | 341,469 | 31,360 | 23,703,082 |
| Jennifer McNealey | 12,366,108 | 338,886 | 31,602 | 23,703,082 |
| 2. | Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 – This proposal was approved as set forth below: |
|
Votes For |
Votes Against |
Abstentions |
| 35,408,410 | 814,759 | 216,509 |
| 3. | Approval, on an advisory basis, of the compensation of the Company’s named executive officers – This proposal was approved as set forth below: |
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
| 11,957,462 | 656,347 | 122,787 | 23,703,082 |
About ENZON PHARMACEUTICALS, INC. (OTCMKTS:ENZN)
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn’s disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.